Clinical Study | Open Access
Joseph M. Lyons, James I. Ito, Servaas A. Morré, "Efficacy of an Immune Modulator in Experimental Chlamydia trachomatis Infection of the Female Genital Tract", Infectious Diseases in Obstetrics and Gynecology, vol. 2006, Article ID 061265, 6 pages, 2006. https://doi.org/10.1155/IDOG/2006/61265
Efficacy of an Immune Modulator in Experimental Chlamydia trachomatis Infection of the Female Genital Tract
Objective. The aim of this study was to determine if vaginal application of the immune response modifier imiquimod (Aldara cream, 3M Pharmaceuticals, St Paul, Minn) would alter the course and/or outcome of female genital tract infection with a human isolate of Chlamydia trachomatis in a murine model. Methods. Groups of CF-1 mice were treated with Aldara on three different schedules: (1) ongoing beginning 5 days prior to and continuing through day 5 of infection; (2) a single prophylactic dose 2 hours prior to infection; and (3) therapeutic from day 4 to day 14 of infection. Mice were infected vaginally with a serovar D strain of C trachomatis, and monitored by culture to determine the level of shedding and duration of infection. Results. We observed a significant reduction in both duration of infection and the level of shedding during the acute phase in mice treated on an ongoing basis commencing 5 days prior to infection. There was no effect with respect to the other regimens. Conclusion. These results demonstrate that ongoing Aldara treatment has efficacy and may enhance local innate immunity which reduces the duration of subsequent infection with human isolates of C trachomatis in a murine model of female genital tract infection.
- R L Miller, J F Gerster, M L Owens, H B Slade, and M A Tomai, “Imiquimod applied topically: a novel immune response modifier and new class of drug,” International Journal of Immunopharmacology, vol. 21, no. 1, pp. 1–14, 1999.
- S K Tyring, I Arany, M A Stanley et al., “A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod,” The Journal of Infectious Diseases, vol. 178, no. 2, pp. 551–555, 1998.
- H Tran, G Moreno, and S Shumack, “Imiquimod as a dermatological therapy,” Expert Opinion on Pharmacotherapy, vol. 5, no. 2, pp. 427–438, 2004.
- D I Bernstein and C J Harrison, “Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections,” Antimicrobial Agents and Chemotherapy, vol. 33, no. 9, pp. 1511–1515, 1989.
- S Buates and G Matlashewski, “Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action,” The Journal of Infectious Diseases, vol. 179, no. 6, pp. 1485–1494, 1999.
- J Gilbert, M M Drehs, and J M Weinberg, “Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection,” Archives of Dermatology, vol. 137, no. 8, pp. 1015–1017, 2001.
- T W Schacker, M Conant, C Thoming, T Stanczak, Z Wang, and M Smith, “Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 10, pp. 3243–3248, 2002.
- I Arevalo, B Ward, R L Miller et al., “Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator,” Clinical Infectious Diseases, vol. 33, no. 11, pp. 1847–1851, 2001.
- J Seeberger, S Daoud, and J Pammer, “Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod,” International Journal of Dermatology, vol. 42, no. 7, pp. 576–579, 2003.
- H Hemmi, T Kaisho, O Takeuchi et al., “Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway,” Nature Immunology, vol. 3, no. 2, pp. 196–200, 2002.
- S J Gibson, J M Lindh, T R Riter et al., “Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod,” Cellular Immunology, vol. 218, no. 1-2, pp. 74–86, 2002.
- A Ambach, B Bonnekoh, M Nguyen, M P Schön, and H Gollnick, “Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro,” Molecular Immunology, vol. 40, no. 18, pp. 1307–1314, 2004.
- F Heil, P Ahmad-Nejad, H Hemmi et al., “The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily,” European Journal of Immunology, vol. 33, no. 11, pp. 2987–2997, 2003.
- A C Gerbase, J T Rowley, D H Heymann, S F Berkley, and P Piot, “Global prevalence and incidence estimates of selected curable STDs,” Sexually Transmitted Infections, vol. 74, no. suppl 1, pp. S12–S16, 1998.
- K A Workowski, M F Lampe, K G Wong, M B Watts, and W E Stamm, “Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection,” JAMA: The Journal of the American Medical Association, vol. 270, no. 17, pp. 2071–2075, 1993.
- I GM van Valkengoed, S A Morré, A JC van den Brule et al., “Follow-up, treatment, and reinfection rates among asymptomatic Chlamydia trachomatis cases in general practice,” British Journal of General Practice, vol. 52, no. 481, pp. 623–627, 2002.
- L R Westrom, R Joesoef, G Reynolds, A Hagdu, and S E Thompson, “Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results,” Sexually Transmitted Diseases, vol. 19, no. 4, pp. 185–192, 1992.
- M E Ward, “The immunobiology and immunopathology of chlamydial infections,” APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 103, no. 11, pp. 769–796, 1995.
- S D Hillis, L M Owens, P A Marchbanks, L F Amsterdam, and W R Mac Kenzie, “Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease,” American Journal of Obstetrics and Gynecology, vol. 176, no. 1 pt 1, pp. 103–107, 1997.
- A Kinnunen, P Molander, R P Morrison et al., “Chlamydial heat shock protein 60—specific T cells in inflamed salpingeal tissue,” Fertility and Sterility, vol. 77, no. 1, pp. 162–166, 2002.
- K A Kelly, “Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms,” International Reviews Of Immunology, vol. 22, no. 1, pp. 3–41, 2003.
- M. Tuffrey and D. Taylor-Robinson, “Progesterone as a key factor in the development of a mouse model for genital-tract infection with Chlamydia trachomatis,” FEMS Microbiology Letters, vol. 12, no. 2, pp. 111–115, 1981.
- J I Jr Ito, J M Lyons, and L P Airo-Brown, “Variation in virulence among oculogenital serovars of Chlamydia trachomatis in experimental genital tract infection,” Infection and Immunity, vol. 58, no. 6, pp. 2021–2023, 1990.
- K T Ripa and P A Mårdh, “Cultivation of Chlamydia trachomatis in cycloheximide-treated mcCoy cells,” Journal of Clinical Microbiology, vol. 6, no. 4, pp. 328–331, 1977.
- K H Ramsey, N Shaba, K P Cohoon, and K A Ault, “Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection,” Infectious Diseases in Obstetrics & Gynecology, vol. 11, no. 2, pp. 81–87, 2003.
- J M Lyons, J I Jr Ito, and S A Morré, “The influence of vaginally applied imiquimod on the course of Chlamydia trachomatis serovar D infection in a murine model,” Infectious Diseases in Obstetrics & Gynecology, vol. 13, no. 1, pp. 1–3, 2005.
- S A Morré, J M Ossewaarde, J Lan et al., “Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis,” Journal of Clinical Microbiology, vol. 36, no. 2, pp. 345–351, 1998.
- J M Lyons, J I Jr Ito, A S Peña, and S A Morré, “Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarum,” Journal of Clinical Pathology, vol. 58, no. 4, pp. 397–401, 2005.
- H D Caldwell, H Wood, D Crane et al., “Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates,” The Journal of Clinical Investigation, vol. 111, no. 11, pp. 1757–1769, 2003.
- R P Morrison, “Differential sensitivities of Chlamydia trachomatis strains to inhibitory effects of gamma interferon,” Infection and Immunity, vol. 68, no. 10, pp. 6038–6040, 2000.
- L L Perry, H Su, K Feilzer et al., “Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN--mediated inhibition,” The Journal of Immunology, vol. 162, no. 6, pp. 3541–3548, 1999.
- J I Jr Ito and J M Lyons, “Role of gamma interferon in controlling murine chlamydial genital tract infection,” Infection and Immunity, vol. 67, no. 10, pp. 5518–5521, 1999.
- J M Carlin, Y Ozaki, G I Byrne, R R Brown, and E C Borden, “Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects,” Experientia, vol. 45, no. 6, pp. 535–541, 1989.
- W L Beatty, T A Belanger, A A Desai, R P Morrison, and G I Byrne, “Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence,” Infection and Immunity, vol. 62, no. 9, pp. 3705–3711, 1994.
- D N Sauder, “Immunomodulatory and pharmacologic properties of imiquimod,” Journal of the American Academy of Dermatology, vol. 43, no. 1 pt 2, pp. S6–S11, 2000.
- S Nair, C McLaughlin, A Weizer et al., “Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation,” The Journal of Immunology, vol. 171, no. 11, pp. 6275–6282, 2003.
- M P Schön and M Schön, “Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod,” Apoptosis, vol. 9, no. 3, pp. 291–298, 2004.
- R P Morrison and H D Caldwell, “Immunity to murine chlamydial genital infection,” Infection and Immunity, vol. 70, no. 6, pp. 2741–2751, 2002.
- S A Morré, J M Lyons, and J I Jr Ito, “Murine models of Chlamydia trachomatis genital tract infection: use of mouse pneumonitis strain versus human strains,” Infection and Immunity, vol. 68, no. 12, pp. 7209–7211, 2000.
Copyright © 2006 Joseph M. Lyons et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.